{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-001102","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.454123+00:00","generated_at":"2026-05-31T05:35:19.703117+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Immunic hosts MS R&D Day, discusses vidofludimus calcium for relapsing and progressive MS","bullets":["Immunic held a multiple sclerosis R&D Day on September 10, 2024.","Presentation focused on vidofludimus calcium (IMU-838) for relapsing and progressive multiple sclerosis.","No specific clinical or financial data from the presentation were disclosed in this 8-K.","The presentation was furnished as Exhibit 99.1 but is not summarized in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-001102","json":"https://secwatch.observer/filing/0001193805-24-001102.json","markdown":"https://secwatch.observer/filing/0001193805-24-001102.md","text":"https://secwatch.observer/filing/0001193805-24-001102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/0001193805-24-001102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/e663880_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:35:19.703117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}